同相位与反相位化学位移MRI鉴别非肿瘤性与肿瘤性及良恶性骨髓病变的价值
研究纳入174例疑似骨肿瘤患者,计算同相位与反相位序列间的信号强度下降百分比,并与最终诊断(非肿瘤性、良性肿瘤性、恶性肿瘤性)比较。非肿瘤性病变平均信号下降36.6%,良性肿瘤性3.19%,恶性肿瘤性3.24%(p<0.001)。化学位移成像鉴别非肿瘤性与肿瘤性病变的敏感度65.9%、特异度94.6%、准确率87.4%,但鉴别良性与恶性肿瘤性病变的敏感度仅9.1%。
要点
- 反相位信号下降百分比有助于区分非肿瘤性骨髓病变与肿瘤性病变。
- 化学位移成像不能有效鉴别恶性骨肿瘤与非含脂良性骨肿瘤。
- 非肿瘤性病变平均信号下降36.6%,显著高于肿瘤性病变的约3%。
关键影像表现/征象
- 反相位序列上非肿瘤性病变平均信号强度下降36.6%,良性肿瘤性病变为3.19%,恶性肿瘤性病变为3.24%(p<0.001)。
诊断标准与关键数值
- 化学位移成像鉴别非肿瘤性与肿瘤性病变:敏感度65.9%,特异度94.6%,阳性预测值80.6%,阴性预测值89.1%,诊断准确率87.4%。
- 化学位移成像鉴别良性肿瘤性与恶性肿瘤性病变:敏感度9.1%,特异度98.4%,阳性预测值85.7%,阴性预测值51.2%,诊断准确率53.1%。
临床应用与阅片要点
- 反相位信号下降百分比可用于辅助区分非肿瘤性骨髓病变与肿瘤性病变。
- 化学位移成像不应用于鉴别恶性骨肿瘤与非含脂良性骨肿瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine its ability of in-phase (IP) and out-of-phase (OOP) chemical shift imaging (CSI) to distinguish non-neoplastic marrow lesions, benign bone tumours and malignant bone tumours.
METHODS: CSI was introduced into our musculoskeletal tumour protocol in May 2018 to aid in characterisation of suspected bone tumours. The % signal intensity (SI) drop between IP and OOP sequences was calculated and compared to the final lesion diagnosis, which was classified as non-neoplastic (NN), benign neoplastic (BN) or malignant neoplastic (MN).
RESULTS: The study included 174 patients (84 males; 90 females: mean age 44.2 years, range 2-87 years). Based on either imaging features (n = 105) or histology (n = 69), 44 lesions (25.3%) were classified as NN, 66 (37.9%) as BN and 64 (36.8%) as MN. Mean % SI drop on OOP for NN lesions was 36.6%, for BN 3.19% and for MN 3.24% (p < 0.001). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy of CSI for differentiating NN from neoplastic lesions were 65.9%, 94.6%, 80.6%, 89.1%% and 87.4% respectively, and for differentiating BN from MN were 9.1%, 98.4%, 85.7%, 51.2 and 53.1% respectively.
CONCLUSION: CSI is accurate for differentiating non-neoplastic and neoplastic marrow lesions, but is of no value in differentiating malignant bone tumours from non-fat containing benign bone tumours.
ADVANCES IN KNOWLEDGE: CSI is of value for differentiating non-neoplastic marrow lesions from neoplastic lesions, but not for differentiating benign bone tumours from malignant bone tumours as has been previously reported.
引用
- van Vucht N, Santiago R, Pressney I, et al. Role of in-phase and out-of-phase chemical shift MRI in differentiation of non-neoplastic versus neoplastic benign and malignant marrow lesions. Br J Radiol. 2021. PMID: 33571012. doi:10.1259/bjr.20200710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。